Abstract: A myofascial device includes a handle having a first end and a second end, a motor at least partially disposed within the handle, a battery at least partially disposed within the handle, and a rotatable assembly disposed between the first end and the second end. The rotatable assembly is configured to rotate during operation of the motor. The rotatable assembly includes a first frame, a second frame, shafts disposed between the first frame and the second frame, first rotatable elements disposed about a first portion of the shafts, and second rotatable elements disposed about a second portion of the shafts.

Abstract: A device includes a first handle formed at least in part by a first housing and a second housing, a second handle formed at least in part by a third housing and a fourth housing, and a rotatable assembly at least partially disposed between the first handle and the second handle. The rotatable assembly is rotatable at least partially about the first housing and the second housing. The rotatable assembly includes shafts, first rotatable elements disposed about a first portion of the shafts, and second rotatable elements disposed about a second portion of the shafts. The first portion of the shafts and the second portion of the shafts are alternatingly disposed around the rotatable assembly.

Abstract: The invention provides analyzers that improve tests for detecting specific cellular, viral, and molecular targets in clinical, industrial, or environmental samples. The invention permits efficient and specific selection and sensitive imaging detection of individual microscopic targets at low magnification. Automated embodiments allow efficient walk-away, on-demand, random-access high-throughput testing. The analyzers perform tests without requiring wash steps thus streamlining engineering and lowering costs. Thus, the invention provides analyzers that can deliver rapid, accurate, and quantitative, easy-to-use, and cost-effective tests for analytes.

Abstract: The invention provides analyzers that improve tests for detecting specific cellular, viral, and molecular targets in clinical, industrial, or environmental samples. The invention permits efficient and specific selection and sensitive imaging detection of individual microscopic targets at low magnification. Automated embodiments allow efficient walk-away, on-demand, random-access high-throughput testing. The analyzers perform tests without requiring wash steps thus streamlining engineering and lowering costs. Thus, the invention provides analyzers that can deliver rapid, accurate, and quantitative, easy-to-use, and cost-effective tests for analytes.

Abstract: Direct-fired supercritical carbon dioxide (CO2) power cycle that generates hydrogen. More specifically, the discharge of a direct fired supercritical CO2 power cycle is converted to carbon dioxide and hydrogen where the hydrogen and/or carbon dioxide can be separated and stored/utilized in another application.

Abstract: Direct-fired supercritical carbon dioxide (CO2) power cycle that generates hydrogen. More specifically, the discharge of a direct fired supercritical CO2 power cycle is converted to carbon dioxide and hydrogen where the hydrogen and/or carbon dioxide can be separated and stored/utilized in another application.

Abstract: Embodiments herein describe using visual passwords to control access to secure information. When a user attempts to access the secure information, she can provide her username to an authentication agent which identifies the visual password corresponding to the received username and selects a first set of images that contains the visual password and a second set of images that does not. The first and second sets of images are then transmitted to a user device. The user device can display the first and second sets of images to the user who selects which images have the visual password. An indication of which images the user selected is then transmitted to the authentication engine which determines whether the user selected all the images in the first set and none of the images in the second set. If so, the user is granted access to the secure information.

Abstract: The present invention is directed to dye mixtures comprising structures of formula and their production and their use for dyeing textiles and in particular for dyeing aramid fibres.

Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: Methods, apparatus, and systems are provided for scanning and measuring an anatomical cavity. An apparatus may include an absorbing medium assembly that is fluidly connected to an earpiece and configured to provide an absorbing medium to the earpiece. The absorbing medium assembly may include a medium container with a gas trap, as well as a tube fluidly connected to the medium container. The gas trap may be located at a top portion of the medium container. The tube may be coupled to the top portion or a bottom portion of the medium container. The system may include a dip tube disposed inside the medium container when the tube of the absorbing medium assembly couples to a top portion of the medium container. A gas relief valve configured to enable gas to escape may also be present in the apparatus.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: The present invention is directed to dye mixtures comprising structures of formula and their production and their use for dyeing textiles and in particular for dyeing aramid fibres.

Abstract: The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a pH in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations.

Abstract: The invention relates to mixtures of fiber-reactive Triphendioxazine dyes with other fiber-reactive azo dyes and their use for the dyeing of hydroxyl- and especially carboxamide-containing material in blue and navy shades.

Abstract: The invention relates to mixtures of fibre-reactive Triphendioxazine dyes with other fibre-reactive azo dyes and their use for the dyeing of hydroxyl- and especially carboxamide-containing material in blue and navy shades.

Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.

Abstract: Provided herein are exemplary compositions, products, and capsules utilizing POA, EPA, blends of POA and EPA, total algal oil compositions, and/or whole biomass compositions in methods of inhibiting inflammation including in cardiovascular disease, diabetes, obesity, stroke, metabolic syndromes, dementia, Alzheimer's disease, and/or cancer. The exemplary compositions, products, and capsules may be orally, topically, intravenously, and/or subcutaneously administered. The exemplary compositions herein may be used as feed, food, food supplements, beverages, beverage supplements, nutritional products, products for athletic performance, pharmaceutical products, and/or medical products for mammalian use, including humans.